Glaukos Corporation
GKOS
$86.16
$0.070.08%
NYSE
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
8/1/2025
-
MarketBeat
8/1/2025
-
MarketBeat
8/1/2025
-
MarketBeat
8/1/2025
-
Simply Wall St
8/1/2025
-
Ticker Report
8/1/2025
-
Fool.com Headlines
7/31/2025
-
TipRanks Financial Blog
7/31/2025
-
Zacks Investment Research
7/31/2025
-
GuruFocus
7/31/2025
-
GuruFocus
7/31/2025
-
GuruFocus
7/31/2025
-
GuruFocus
7/31/2025
-
The Fly
7/31/2025
-
TipRanks Financial Blog
7/31/2025
-
The Fly
7/31/2025
-
SeekingAlpha
7/31/2025
-
SeekingAlpha
7/31/2025
-
Seeking Alpha: Transcripts
7/31/2025
-
GuruFocus
7/30/2025
-
Zacks Investment Research
7/30/2025
-
GuruFocus
7/30/2025
-
GuruFocus
Glaukos Corp (GKOS) Q2 2025 Earnings: EPS of -$0.34 Beats Estimate, Revenue Surges to $124.1 Million
7/30/2025
-
GuruFocus
7/30/2025
-
GuruFocus
7/30/2025
-
The Fly
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, May 1, 2025
Period Date
Monday, March 31, 2025
Next Filing
Beginning of August (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
949 367 9600
Address
One Glaukos Way
Aliso Viejo, CA 92656
Aliso Viejo, CA 92656
Country
Year Founded
Business Description
Sector
Industry
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States...
more